Search

A program is carried out with heart patients to study the effect of the angiotensin receptor blocker candesartan on myocardial infarction (MI) and other coronary disorders. Findings prove that the danger of the combined outcome of cardiovascular death or nonfatal MI markedly decreases with candesartan.

Thrombolytic therapy may be used to prevent another heart attack in patients who have already suffered a severe heart attack. Thrombolytic therapy is treatment with different drugs to break up blood clots. A survey of the medical literature found that thrombolytic therapy can significantly decrease the number of complications and deaths among patients who have suffered a severe heart attack. Many patients who would benefit from this type of treatment do not receive it for a variety of reasons. Patients with high blood pressure or who have received cardiopulmonary resuscitation (CPR) often do not receive thrombolytic therapy, even though these conditions only slightly decrease their chance of benefiting from treatment. Elderly patients who have had a heart attack should not excluded from treatment on the basis on their age.

The article presents a study which examines the role of hemoglobin A1c levels as progressive risk factors for cardiovascular (CV) events in patients with symptomatic chronic heart failure (HF). The study focused on participants of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. An analysis of the incidence of cardiovascular death, hospitalization for heart failure and total mortality in patients with chronic heart failure was also conducted.